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Abstract
Background: CRISPR-Cas systems have been broadly embraced as effective tools for genome engineering
applications, with most studies to date utilizing the Streptococcus pyogenes Cas9. Here we characterize and
manipulate the smaller, 1053 amino acid nuclease Staphylococcus aureus Cas9.
Results: We find that the S. aureus Cas9 recognizes an NNGRRT protospacer adjacent motif (PAM) and cleaves
target DNA at high efficiency with a variety of guide RNA (gRNA) spacer lengths. When directed against genomic
targets with mutually permissive NGGRRT PAMs, the S. pyogenes Cas9 and S. aureus Cas9 yield indels at comparable
rates. We additionally show D10A and N580A paired nickase activity with S. aureus Cas9, and we further package it
with two gRNAs in a single functional adeno-associated virus (AAV) vector. Finally, we assess comparative S.
pyogenes and S. aureus Cas9 specificity using GUIDE-seq.
Conclusion: Our results reveal an S. aureus Cas9 that is effective for a variety of genome engineering purposes,
including paired nickase approaches and all-in-one delivery of Cas9 and multiple gRNA expression cassettes with
AAV vectors.
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Background
The initial characterizations of CRISPR-Cas systems as
mechanisms of bacterial and archaeal adaptive immunity
[1–3] led to demonstrations of guide RNA (gRNA)-tar-
geted DNA cleavage in vitro by the type II CRISPR-Cas
nuclease Cas9 [4], and further experiments revealed the
usefulness of these systems for genome engineering [5, 6].
Cas9 can be specifically targeted to any locus of interest,
whereupon it cleaves the DNA, stimulating a variety of
DNA damage response mechanisms that can lead to
knockouts, gene conversions, and gene corrections [7].
Unlike its predecessors (zinc finger nucleases, TAL
effector nucleases), however, whose targeting is based on
modular, protein-based recognition domains that must be
rearranged for each new target site, the Cas9 enzyme rec-
ognizes target DNA sequences by Watson–Crick base
pairing between its gRNA and the target.
These developments have been broadly welcomed by
the research community, which has embraced the
Streptococcus pyogenes Cas9 (SpCas9), a 1368 amino acid
variant whose only targeting limitation is the require-
ment of a protospacer adjacent motif (PAM) consisting
of NGG nucleotides immediately 3′ to the target site [8].
In the few years since its debut, the SpCas9 has been
successfully used in a plethora of model and commer-
cially valuable organisms [5, 6, 9–11] and has been the
subject of extensive characterizations and modifications.
Cas9 nucleases from other bacterial species, such as
Streptococcus thermophilus, Neisseria meningitides, and
Staphylococcus aureus, have also been identified, and
preliminary characterizations reveal substantial varia-
tions in size, PAM sequence requirements, and DNA
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cleavage efficiencies [12, 13]. Here we report further in-
sights and tool developments related to the S. aureus
Cas9 (SaCas9), a 1053 amino acid protein that may
provide substantial advantages due to its size and
efficacy [13].
Results and discussion
To corroborate the reported PAM recognition sequence
of NNGRRT [13], we utilized a luciferase reporter assay
in which HEK293T cells were transfected with a SaCas9/
gRNA dual expression plasmid (pCMVSau) along with
one of a series of firefly luciferase indicator plasmids,
each containing a different PAM sequence adjacent to
the invariant target site [14] (Figure S1 and Table S1 in
Additional file 1). Results of this assay, where strong lu-
ciferase knockdown indicates robust SaCas9 cleavage of
the target plasmid, show highest targeting efficiency at
NNGRRT PAMs, and moderate cleavage of targets with
NNGRRV PAMs (Fig. 1a). To determine whether this
activity profile is maintained at endogenous loci, we



















































































































































Fig. 1 SaCas9 PAM characterization and gRNA spacer length assessment in HEK293, HEK293T, HEK293FT, and HEK293-GFP cells. a A plasmid-
based, luciferase knockdown assay in which an invariant target sequence with variable PAMs was placed at the 5′ end of luciferase. Data are
shown as means ± standard error of the mean (SEM) (N = 3). b T7E1-measured indel rates resulting from SaCas9 directed to endogenous targets
with NNGRRT and NNGRRV PAMs. Data are shown as means ± SEM (N = 2). An unpaired t-test for the two groups yields a P value of <0.0001.
c Comparisons of indel rates between SaCas9 and SpCas9 at targets with overlapping (NGGRR(T)) PAMs. Data are shown as means ± SEM
(N = 2). N.D. none detected. d Indel rates resulting from SaCas9 directed to endogenous VEGFA (top) and CCR5 (bottom) targets, with gRNAs of
varying spacer length. “Sibling” gRNAs target the same precise locus, initiate with a target-matching G, and are marked with same-colored dots.
Orange bars represent mean cleavage (±SEM (N ≥ 3)) for gRNAs of that length. N.D. none detected. Middle: Knockdown of green fluorescent
protein (GFP) in HEK293-GFP cells as measured by percentage of cell population that is GFP-negative 3.5 days post-transfection
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designed gRNA constructs directing SaCas9 to target
sites in the human VEGFA and B2M loci with either
NNGRRT or NNGRRV PAMs (Fig. 1b). These gRNAs
were designed with spacer lengths of 24 nucleotides and
a target-matching 5′ G to encourage consistent expres-
sion from the U6 promoter. We assayed cleavage of tar-
get DNA and the resulting formation of insertions and
deletions (indels) that arise via imperfect repair of the
DNA through non-homologous end joining (NHEJ) of
these double-strand breaks (DSBs). At these endogenous
loci, there was a substantial preference for the NNGRRT
PAMs, though target sites with NNGRRV PAMs still
permitted some nuclease activity.
Because the SaCas9 and SpCas9 PAM sequences are
not mutually exclusive, we directly compared the two
nucleases at identical target sites with overlapping PAMs
consisting of NGGRR(T) (Fig. 1c). SaCas9 gRNAs were
24-mers initiating with a target-matching 5′ G, while
SpCas9 gRNAs were 20-mers with an additional 5′ G
(21-mers). Results indicate that when the SaCas9
(pAF003) was directed to targets with its preferred
NNGRRT PAM, cleavage efficiencies between it and
SpCas9 (pAF028) were comparable, with SaCas9 outper-
forming SpCas9 in some cases. As expected, when
SaCas9 was directed to target sites with NNGRRV
PAMs, significantly less DNA cleavage was observed
compared with SpCas9-induced cleavage.
We next varied the length of the gRNA spacer se-
quence to determine the optimum for maximal DNA
cleavage when in complex with SaCas9. Beginning with
a selection of effective 24-mer spacers from Fig. 1b and
an additional 23-mer spacer (VEGFA-15) targeting a
~500-bp region of the VEGFA gene, we generated all
available G-initiating “sibling” gRNAs, which have
spacers of different lengths but target the same site.
With this strategy, the initial group of 12 24-mer gRNAs
expanded to 44 gRNAs with spacer lengths ranging from
24 to 15 bases, all with a target-matching 5′ G. Results
from this experiment show that maximum gRNA effi-
ciencies can be achieved with spacer lengths ranging
from 24-mers down to 20-mers, that 19-mers and 18-
mers can still have some activity, and that 17-mers and
shorter are inactive (Fig. 1d, top). To increase the
resolution around the 20 base to 17 base window, we
designed gRNAs for a second, similar experiment tar-
geting sites at a second locus, CCR5 (Fig. 1d, bottom).
A third such experiment, this time with gRNAs de-
signed to knock out an integrated green fluorescent
protein (GFP) from HEK293-GFP cells, was carried out
to further increase the total number of sites tested
(Fig. 1d, middle). Taken together, these data show the
effectiveness of gRNAs across a range of spacer lengths,
with sequences of 24 to 20 bases working most
efficiently.
Next, we constructed two SaCas9 nickases by aligning
the amino acid sequence to that of SpCas9 and identify-
ing residues corresponding to the previously described
D10A and N863A substitutions [15] (Figure S2 in
Additional file 1). We used site-directed mutagenesis to
generate D10A and N580A mutants that would similarly
disable the RuvC and HNH nuclease domains, respect-
ively. We selected five gRNAs from those shown in
Fig. 1b that yielded high levels of indels and whose ori-
entations with respect to each other make them suitable
for use as nickase pairs (Fig. 2a), and transfected them
individually and as pairs with the wild-type (pAF003),
D10A (pAF008), and N580A (pAF009) SaCas9 plasmids.
Sequencing of the locus showed that the nickases had
minimal activity when transfected with a single gRNA;
N580A typically yielded no indels and D10A yielded
indel rates between 0 % and ~8 %. Cells that were trans-
fected with a nickase and two gRNAs, on the other
hand, yielded indels with a range of efficiencies extend-
ing up to ~60 %. Interestingly, the D10A nickase consist-
ently outperformed the N580 nickase (Fig. 2b). Their
respective indel distributions were also substantially dif-
ferent, with D10A indels evenly split between insertions
and deletions, while N580A indels were predominantly
insertions. Wild-type SaCas9 indels were predominantly
deletions (Fig. 2c).
To further characterize features of the SaCas9 paired
nickases, we selected an array of gRNAs that efficiently
induced indels at their targets when expressed with
wild-type SaCas9 (Figure S3 and Tables S1 and S2 in
Additional file 1) and transfected them with the D10A
mutant as pairs with offset distances ranging from ap-
proximately -150 bp to 200 bp (Fig. 2d). Pairs of gRNAs
with offsets below zero yielded minimal indel rates,
while most gRNA pairs with offsets between 0 and
125 bp yielded substantial indel rates. Surprisingly, and
in contrast with SpCas9 data previously reported [15],
some gRNA pairs with offsets between 125 and 170 bp
yielded modest indel rates. These data reflect the general
effectiveness of the D10A SaCas9 nickase; however,
other properties of the SaCas9 nickases, such as whether
they can shift the balance between homology-dependent
repair and NHEJ, and/or whether they can reduce off-
target DNA cleavage compared with the wild-type nucle-
ase (features reported for other nickases [15, 16]) war-
rant future attention.
We also made use of the small size of the SaCas9 and
packaged it along with two U6-promoter-driven gRNAs
in a single adeno-associated virus (AAV). The SaCas9 is
encoded by 3159 bp, leaving ~1.8 kb of space for regula-
tory elements and gRNAs given the ~5.0 kb packaging
limit of AAVs [17]. Here, we drove the SaCas9 expres-
sion with an EFS promoter and added a mini poly(A) tail
to its 3′ end (Fig. 3a). We made seven such vectors: the
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first with the SaCas9 expression cassette (with its EFS
promoter and poly(A) tail) and a U6-promoter-driven
gRNA targeting VEGFA, the second with the SaCas9
cassette and a U6-promoter-driven gRNA targeting
CCR5, and the third with the SaCas9 expression cassette
and both the aforementioned gRNA cassettes. The
other four vectors we constructed contained D10A
SaCas9 expression cassettes along with various pairs
of VEGFA-targeting gRNA cassettes (Fig. 3d). We
packaged these AAVs with a serotype 2 capsid, then
transduced HEK293 and HEK293FT cells. Western
blots confirmed the expression of SaCas9 in all trans-
duced samples (Fig. 3c, f ), while T7E1 assays and se-
quencing showed a range of Cas9 activity at targeted
loci (Fig. 3b, e, respectively).
This ability to package two gRNAs and SaCas9 in a
single AAV opens the door to additional gene editing
approaches using “all-in-one” AAV vectors, such as
targeted deletions mediated by wild-type SaCas9 and
two gRNAs, and multiplexed knockouts. With the
current total vector length of 4859 bp, it is conceivable
that a third gRNA could be added to these vectors
given further reductions in the size of the regulatory
sequences used. To this end, it may be helpful to use
human tRNA promoters, which are only ~70 bp in size,
and were recently demonstrated to be as effective as
the ~250 bp U6 promoter used here in driving gRNA
expression [18]. Moreover, it may also be possible to
delete some non-essential sequences from the SaCas9
gene itself without reducing nuclease activity or
specificity.
Finally, we conducted a GUIDE-seq experiment
(Fig. 4a, b) to assay SaCas9 specificity compared with
SpCas9 with a gRNA that has a target (VEGFA site 3)
with known off-target sites [19, 20]. Our experiment, in
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Fig. 2 D10A and N580A SaCas9 nickase data. a Sequence of the target locus (VEGFA) with five gRNAs annotated in grey. b Wild-type (WT) SaCas9,
D10A and N580A SaCas9 nickases generating indels with single and dual gRNAs. Percentage indels on the y-axis represents on-target cleavage
rates as measured by TOPO sequencing. Data are shown as means ± standard error of the mean (SEM) (N = 2). N.D. none detected. c Indel
distribution of insertions and deletions from each SaCas9 type. Wild-type SaCas9 data shown are from transfections with single gRNAs,
whereas D10A and N580A data shown are from transfections with dual gRNAs. d Indel rates as measured by TOPO sequencing for D10A
SaCas9 and pairs of gRNAs with offset distances (between the 5′ ends of the gRNAs) ranging from -150 bp to 200 bp
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length is 20 bases, identified a substantial number of the
SpCas9 off-target sites found previously, with read
counts at some off-target sites nearly as high as those
for the on-target site. In contrast, our GUIDE-seq results
for SaCas9 show a high number of on-target reads but
only single-digit read counts for comparatively fewer off-
targets. Interestingly, all eight of the SaCas9 off-target
sites identified in this experiment were also identified as
off-targets for SpCas9.
Additional experiments will be required to accurately
determine the indel rates at these off-target sites;
however, the read counts suggest that SaCas9 is, in this
case, more specific than SpCas9 when directed by a
20-bp spacer. To further support the use of SaCas9 for
genome engineering, it will be important to use such
minimally biased techniques to evaluate its specificity
at other loci, and with gRNAs of a variety of lengths.
Existing BLESS data similarly indicate SaCas9 is more
specific than SpCas9 at two other target loci, but this
could vary by gRNA and target sequence [13]. These
and other characterizations are likely to be of strong
interest to the genome engineering community given
the array of in vitro, in vivo, and therapeutic applica-
tions that may be facilitated by this smaller, high-
efficiency Cas9.
Conclusions
The S. aureus Cas9 has a number of properties that
make it advantageous for genome editing, including its
small size, high efficiency, nickase activity, and apparent
specificity. Here we characterized a number of salient
features of the wild-type SaCas9 as well as the nickase
variants that we engineered.
We found that SaCas9 principally recognizes an
NNGRRT PAM, and that it cleaves target DNA at rates
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Fig. 3 a. AAV constructs containing SaCas9 with a U6 promoter driving a VEGFA-15 gRNA, with a U6 promoter driving a CCR5-L2 gRNA, and with
both U6-gRNAs. b Indel rates at VEGFA and CCR5 loci as measured by T7E1. Data are shown as means ± standard error of the mean (SEM) (N≥ 3).
N.D. none detected. c Western blots for Flag (SaCas9) and Tubulin confirming expression of SaCas9 in transduced cells. d AAV constructs containing
D10A SaCas9 with different pairs of VEGFA-targeting gRNA expression cassettes. e Indel rates at VEGFA as measured by TOPO cloning and sequencing.
Data are shown as means ± SEM (N = 2). N.D. none detected. f Western blots for Flag (SaCas9) and GAPDH confirming expression of D10A SaCas9 in
transduced cells
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gRNA spacer lengths necessary for SaCas9-mediated target
cleavage, finding robust activity when spacer lengths were 24
to 20 nucleotides. Building on these findings, we generated
SaCas9 nickases and assayed their functionality with a set of
suitable gRNApairs. TheD10A nickase consistently displayed
more activity than the N580A nickase, inducing indels with
frequencies as high as ~60 %. We explored the efficiency of
D10A SaCas9 with gRNA pairs at a range of distances, finding
activity with pairs offset from~0 to ~170 bp.
We also highlighted one of the major advantages of
SaCas9, exploiting its small size to package it in an
AAV with two gRNAs. These viruses were effective at
both simultaneously inducing indels in multiple genes
with the wild-type SaCas9 as well as inducing indels at
single target loci with the D10A SaCas9.
Finally, we performed specificity experiments using the
GUIDE-seq technique. Our results corroborate previously
identified SpCas9 off-target sites for a known gRNA, and
we moreover found that SaCas9 induces DSBs at a subset
of these sites with significantly lower read counts.
Taken together, our characterizations and manipu-
lations of SaCas9 reveal a valuable set of tools for a
wide array of CRISPR-based genome engineering
applications.
Fig. 4 a Sequences of off-target sites identified by GUIDE-seq for SpCas9 and SaCas9 when directed by gRNA to VEGFA site 3. The intended
target sequence is shown in the top line with the guide sequence on the left and the PAM on the right. On-target reads are shown in bold, and
mismatches found in off-target sequences are highlighted in color. Off-target sites found in both datasets are matched with grey lines. Previously
identified SpCas9 off-target sites are indicated with asterisks. b Histograms of mapped reads at off-target loci
Fig. 1a (luciferase) Cell type: HEK293T
Fig. 1b (NNGRR(T/V)) Cell type: HEK293
Fig. 1c (SaCas9 vs SpCas9) Cell type: HEK293FT
Fig. 1d (top) (gRNA length — VEGFA) Cell type: HEK293
Fig. 1d (mid) (gRNA length — GFP) Cell type: HEK293-GFP
Fig. 1d (bottom) (gRNA length — CCR5) Cell type: HEK293
Fig. 2b–d (nickases) Cell type: HEK293FT
Fig. 3a–c (AAV transduction) Cell type: HEK293
Fig. 3d–f (AAV transduction) Cell type: HEK293FT
Fig. 4a, b (GUIDE-seq) Cell type: U-2 OS
Materials and methods
Cell types used
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Cell culture
HEK293, HEK293FT (Life Technologies, catalog #R700-
07), HEK293-GFP (GenTarget, catalog #SC001), and U2-
OS (ATCC #HTB-96) cells were maintained in Dulbec-
co’s modified Eagle medium (DMEM; Life Technologies)
supplemented with 10 % fetal bovine serum (FBS), 5 %
penicillin/streptomycin, and 2 mM Glutamax. Cells were
kept at 37 °C in a 5 % CO2 incubator.
Plasmid and gRNA construction
The pCMVSau plasmid expressing a human codon op-
timized SaCas9 and a customizable U6-driven gRNA
scaffold have been previously described [18]. Cognate
luciferase indicator constructs were generated as pre-
viously described [14]. Maps of these plasmids and all
other SaCas9 plasmids are shown in Figure S1 in
Additional file 1.
gRNA used in Fig. 1a was generated by cloning
annealed oligos containing the target sequence into
pCMVSau. gRNAs used for data shown in Figs. 1b–d
and 2d were generated by PCR and transfected as ampli-
cons containing U6 promoter, spacer sequence, and
TRACR scaffold. gRNAs used for data shown in Figs. 2b,
c and 4a, b were generated by ligating either one or two
of these into a pUC19 backbone vector via Gibson As-
sembly (New England Biolabs).
AAV vectors used in Fig. 3a–c were constructed by
Gibson Assembly of one or two gRNA cassettes into
SaCas9-containing AAV backbone pSS3. Vectors used in
Fig. 3d–f were constructed by subcloning gRNA cassette
pairs from vectors pAF089, pAF091, pAF092 into pSS60.
Inverted terminal repeats (ITRs) were confirmed by
XmaI digest of the vectors.
Transfections
Cells were seeded at a density of 100,000 cells/well in
24-well plates. After 24 hours, cells were transfected
with 250 ng of gRNA plasmid or amplicon and 750 ng
of either wild-type Cas9 plasmid, Cas9-D10A nickase
plasmid, or Cas9-N580A nickase plasmid. All transfec-
tions were performed in duplicate using either Lipofecta-
mine 3000 (Life Technologies) or MirusTransIT-293
reagent (Mirus Bio).
Luciferase analysis
293T cells were seeded at 1.25 × 105 cells per well in 12-
well plates. Cells were transfected using the calcium
phosphate method with 1 μg of the SaCas9/gRNA ex-
pression vector, 250 ng of a cognate gRNA firefly lucifer-
ase indicator plasmid, and 10 ng of a renilla luciferase
internal control plasmid. Transfected cells were har-
vested 72 hours post-tranfection and lysed in Passive
Lysis Buffer (Promega) and then assayed for luciferase
activity using a Dual Luciferase Assay Kit (Promega).
GFP analysis
At 3.5 days post-transfection, cells had their media re-
moved and were washed with 500 μl of phosphate-
buffered saline (PBS). Next, 200 μl of trypsin was added
to the cells and they were incubated at 37 °C with 5 %
CO2 for 5 min. Trypsinization was halted by adding
500 μl of complete media to each well. Cells were col-
lected from each well and transferred to eppendorf
tubes, spun down at 3000 rpm for 7 min, washed with
1 ml fluorescence-activated cell sorting (FACS) buffer
(PBS with 3 % FBS) and spun down again, and finally re-
suspended in 200 μl FACS buffer. Cells were then ana-
lyzed with a BD Accuri C6 flow cytometer.
DNA analysis
DNA was harvested 72 hours post-transfection or post-
infection using an Agencourt DNAdvance genomic DNA
isolation kit (Beckman) with a 4 hour lysing period, ac-
cording to the manufacturer’s directions. Genomic DNA
was then purified using Agencourt AMPure XP beads
(Beckman) as per the manufacturer’s protocol.
For T7E1 assays, locus PCRs were performed to amplify
regions of VEGFA, CCR5, and B2M. All reactions were
performed with Phusion high-fidelity DNA polymerase
(New England Biolabs) with resulting products purified by
Agencourt AMPure XP beads (Beckman) according to the
manufacturer’s instructions. T7E1 digestion was then per-
formed in NEB Buffer 2 according to manufacturer’s in-
structions and resulting cleavage products were analyzed
on a Qiagen QIAxcel Advanced System (Qiagen).
PCR conditions (Table S3 in Additional file 1).
For nickase assays, amplified VEGFA locus fragments
were cloned into pCR4-TOPO vector using ZeroBlunt
TOPO Cloning Kit (Life Technologies). TOPO reaction
products were then transformed in One Shot Top10
chemically competent Escherichia coli cells. Cells were
plated on carbenicillin LB agar plates and incubated
overnight at 37 °C. Plasmid DNA was sequenced by
Macrogen Corp. and Genewiz, Inc. using an M13 for-
ward primer.
Viral vector production and titration
HEK293 cells were maintained in DMEM supplemented
with 10 % FBS, 100 U/ml penicillin, and 100 U/ml
Locus: VEGF(1) Primers: OME6/OME8 Annealing Temp: 67.5 °C
Locus: VEGF(2) Primers: AF116/AF117 Annealing Temp: 64 °C
Locus: CCR5(1) Primers: AF205/AF208 Annealing Temp: 64 °C
Locus: CCR5(2) Primers: AF209/AF211 Annealing Temp: 64 °C
Locus: B2M Primers: GWED67/68 Annealing Temp: 65 °C
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streptomycin on 150-mm petri dishes in 5 % CO2 at
37 °C incubation. HEK293 cells were split 1:3 at
18 hours prior to transfection. AAV2 vectors were
packaged with the “triple transfection” method using
three plasmids: (1) 60 μg of pHelper (Cell Biolabs, Inc.,
San Diego, CA, USA) expressing E2A, E4, and VA from
adenovirus; (2) 50 μg of pRC2 expressing Rep2 and
Cap2 from AAV2 (Cell Biolabs, Inc.); and (3) 30 μg of
pSS/pAF plasmids with ITRs from wild-type AAV2 and
CRISPR components. Mirus TransIT-293 reagent
(420 μl; Mirus Bio LLC, Madison, WI, USA) was mixed
with 14 ml of OptiMEM and incubated at room
temperature for 10 min before being added to the mix-
ture of three packaging plasmids. After another 10-min
incubation, the transfection mix was evenly distributed
to five plates of HEK293 cells. At 70 hours post-
transfection, supernatants and HEK293 production cells
were collected by pelleting and centrifugation. Cell pel-
lets underwent sonication, CsCl ultracentrifugation,
and dialysis with 1× PBS to yield recombinant AAV2
viral particles.
To titrate AAV2 preparations, 10 μl of dialyzed viral
vector was incubated in 90 μl of DNaseI solution at 37 °C
for 1 hour, followed by serial dilution with ddH2O. Drop-
lets were generated with Bio-Rad QX200 using 70 μl of
droplet generation oil and 20 μl of samples including
probe, saCas9-1-Probe (5′-6FAM-catcgggattacaagcgtggggt
atggg-MGB-NFQ-3′), and primers, OliSS67 (5′-gaactac
attctggggctgg-3′) and OliSS68 (5′-acgttggcctccttgaacag-
3′). PCR reactions were carried out with 40 μl of droplet
mix on a regular thermocycler. Droplets were read with
Bio-Rad QX200 system to quantify positive and negative
droplets. Viral vector titers were obtained by multiplying
ddPCR readouts and dilution factors.
Vector transduction and western blotting
HEK293 cells were plated at a density of 100,000 cells/
well in a 24-well plate and transduced with AAV2 vec-
tors packaging U6-driven gRNA and EFS-driven SaCas9
at a multiplicity of infection (MOI) of 10,000 viral gen-
ome (vg)/cell. Growth medium was aspirated off the 24-
well plate 72 hours post-transduction and cells were
lysed with lysis buffer from the Agencourt DNAdvance
kit (Beckman Coulter, Brea, CA, USA) followed by
genomic DNA (gDNA) extraction, locus PCR (VEGF
and CCR5 loci), and T7E1 assay to quantify genomic
modification.
For western blotting, cells were lysed with 1× RIPA
buffer with 1× cOmplete ULTRA protease inhibitor
cocktail (Roche Diagnostics Corporation, Indianapolis,
IN, USA) and 1× PhosSTOP phosphatase inhibitor cock-
tail (Roche Diagnostics Corporation, Indianapolis, IN,
SUA) at 72 hours post-transduction. Cells were lysed at
4 °C for 15 min and lysates were spun down at 13.3
krpm for 15 min at 4 °C. Supernatants were collected
and protein concentrations were quantified using Pierce
BCA protein assay kit (Life Technologies, Carlsbad, CA,
USA). Total protein (41.7 μg) was subjected to 4–12 %
NuPAGE Bis-Tris gel electrophoresis at 150 V for
75 min. Gel transfer was performed using High Molecu-
lar Weight program on the Trans-Blot Turbo Transfer
System (BioRad, Hercules, CA, USA). After blotting with
5 % milk in 1× PBS-T, western blots were incubated sep-
arately with corresponding primary antibodies overnight:
(1) mouse-anti-Flag (clone m2, F3165, Sigma-Aldrich, St
Louis, MO, USA) at 1:1000 dilution in 5 % milk in PBS-
T, and (2) mouse-anti-alpha tubulin (clone B7, sc-5286,
Santa Cruz Biotechnology, Dallas, TX, USA) at 1:200 di-
lution in 5 % milk in PBS-T. Blots were washed with
PBS-T three times prior to incubation with secondary
antibody, goat-anti-mouse IgG-HRP (sc-2005, Santa
Cruz Biotechnology, Dallas, TX, USA), at 1:5000 dilution
in 5 % milk in TBS-T at room temperature for 1 hour.
After four washes with 1× PBS-T, western blots were de-
veloped with Western Lightning Plus-ECL (Perkin
Elmer, Waltham, MA, USA) and imaged.
Guide-seq
U-2 OS cells were maintained in DMEM (Life Technolo-
gies) supplemented with 10 % FBS, 1 % penicillin/
streptomycin. Cells were kept at 37 °C in a 5 % CO2 in-
cubator. Cells were nucleofected at a density of 200,000/
well with 250 ng of gRNA plasmid (pAF015), 500 ng
SaCas9 plasmid (pAF003), and 100 pmol dsODN [19]
using SE Cell line nucleofection solution and the DN-
100 program on a Lonza 4D- nulceofector (V02.16). The
nucleofected cells were seeded in 1 ml media in a 24-
well plate and media was changed 12 hours post-
nucleofection. Cells were grown for 72 hours post-
nucleofection and gDNA was harvested using an Agen-
court DNAdvance gDNA extraction kit. dsODN integra-
tion at the target site was confirmed by restriction
fragment length polymorphism assay with NdeI.
gDNA was quantified with the qubit high sensitivity
dsDNA assay kit. Roughly 400 ng of gDNA from
SpCas9-treated cells and 180 ng of gDNA from SaCas9-
treated cells were sheared acoustically via the Covaris
m220 instrument to an average length of 500 bp in a
total volume of 130 μl 1× TE. The sheared product was
concentrated by AMPure (1× ratio) according to the
manufacturer's protocol and eluted in 15 μl of 1× TE.
One microliter of the product was run on the Agilent
Tapestation system using the D1000 tape to confirm ap-
propriate sizing. The remaining 14 μl of the sheared
DNA was end-repaired, A-tailed, and adapter ligated.
Adapter-ligated product was cleaned via AMPure (0.9×),
eluted in 10 μl 1× TE, and split into sense and anti-
sense PCR reactions. Post-PCR products were cleaned
Friedland et al. Genome Biology  (2015) 16:257 Page 8 of 10
via AMPure (1.2×) and eluted in 15 μl of 1× TE. A sec-
ond round of PCR was then conducted to incorporate
the P7 illumina adapter and capture bi-directionality of
off-target sites based on dsODN incorporated at each
site. The final PCR product was cleaned via AMPure
(0.7×) and eluted in 30 μl 1× TE. One microliter of each
reaction was analyzed via Agilent Tapestation system
using the D1000 screen tape and quantified using the
qubit high sensitivity dsDNA assay kit. Finally, each re-
action was normalized into one library pool and se-
quenced on the Illumina Miseq according to the
manufacturer's protocols.
We analyzed GUIDE-seq data following the method de-
scribed in Tsai et al. [19]. Reads were aligned to the UCSC
hg19 genome assembly using bowtie2 (PMID:22388286).
We selected regions passing the bidirectional filter [19] or
with reads originating at the presumptive cutting site
(three bases away from the PAM).
Supporting data
MiSeq sequence data gathered for the GUIDE-seq ex-
periment (Fig. 4) were deposited in the Sequence Read
Archive (SRA) at NCBI with BioProject number
PRJNA298919. The SpCas9 sense, antisense, and bar-
code data can be accessed via accession numbers
SRX1341497, SRX1341608, and SRX1341607, respect-
ively. The SaCas9 sense, antisense, and barcode data can
be accessed via accession numbers SRX1341609,
SRX1341611, and SRX1341610, respectively.
Additional file
Additional file 1: Supplementary figures and tables, which include
plasmid maps, amino acid sequence alignments, indel data, and
gRNA sequences. (DOCX 2159 kb)
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